<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">NAT</journal-id><journal-title-group><journal-title>Hans Journal of Nanotechnology</journal-title></journal-title-group><issn pub-type="epub">2161-086X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/NAT.2016.62004</article-id><article-id pub-id-type="publisher-id">NAT-17565</article-id><article-categories><subj-group subj-group-type="heading"><subject>NAT20160200000_95932722.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>化学与材料</subject></subj-group></article-categories><title-group><article-title>
 
 
  半乳糖修饰的海藻酸纳米载体构建及其抗肿瘤功效
  Fabrication of Galactosylated Alginate Nanoparticles as Drug Delivery System for Hepatocellular Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>政雄</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>晓盈</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>复旦大学生命科学学院，遗传国家重点实验室，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>13210700138@fudan.edu.cn(吴晓)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>05</month><year>2016</year></pub-date><volume>06</volume><issue>02</issue><fpage>23</fpage><lpage>32</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   本文设计制备肝靶向聚合物纳米粒–半乳糖(Gal)修饰海藻酸酯(HA-Gal)纳米粒，以阿霉素(DOX)为抗肿瘤模型药物制备载药纳米粒(DOX/HA-Gal)，研究DOX/HA-Gal的理化性质、载药与释药、体外细胞增殖抑制，考察不同Gal接枝比对体外抗肿瘤功效的影响。结果表明DOX/HA-Gal为大小均一的球形粒子，水合动力学粒径为180-250nm，荷负电(&lt;−30 mV)；随Gal接枝比的增大，DOX/HA-Gal的粒径增大，Zeta电势升高，包封率增加，肿瘤细胞杀伤率提高。 The alginate derivative naonoparticles modified by galactose (HA-Gal) with various galactose (Gal) substitution degrees were synthesized to evaluate their potential for hepatocellular carcinoma (HCC) targeting. Their physicochemical characteristics were investigated. Doxorubicin hydrochloride (DOX) as a model antitumor drug was incorporated into the HA-Gal. The in vitro drug release and antitumor capability of DOX loaded HA-Gal (DOX/HA-Gal) with different Gal substitution degrees were evaluated. Negatively charged DOX/HA-Gal appeared monodisperse and spherical in shape with a size range of 180 - 250 nm, and their Zeta potentials were above 30 mV (absolute value). The size, Zeta potentials, encapsulation efficiency and in vitro cytotoxicity of HA-Gal were increased with the increment in Gal substitution degree.
    
  
 
</p></abstract><kwd-group><kwd>肝癌，海藻酸纳米粒，半乳糖，药物递送，DOX, Hepatocellular Carcinoma</kwd><kwd> Alginate Nanoparticle</kwd><kwd> Galactose</kwd><kwd> Drug Delivery</kwd><kwd> DOX</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>半乳糖修饰的海藻酸纳米载体构建及其抗肿瘤功效<sup> </sup></title><p>李政雄，吴晓盈<sup>*</sup></p><p>复旦大学生命科学学院，遗传国家重点实验室，上海</p><disp-formula id="hanspub.17565-formula1"><graphic xlink:href="http://html.hanspub.org/file/1-1290076x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年4月5日；录用日期：2016年5月14日；发布日期：2016年5月17日</p><disp-formula id="hanspub.17565-formula2"><graphic xlink:href="http://html.hanspub.org/file/1-1290076x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>本文设计制备肝靶向聚合物纳米粒–半乳糖(Gal)修饰海藻酸酯(HA-Gal)纳米粒，以阿霉素(DOX)为抗肿瘤模型药物制备载药纳米粒(DOX/HA-Gal)，研究DOX/HA-Gal的理化性质、载药与释药、体外细胞增殖抑制，考察不同Gal接枝比对体外抗肿瘤功效的影响。结果表明DOX/HA-Gal为大小均一的球形粒子，水合动力学粒径为180~250 nm，荷负电(&lt;−30 mV)；随Gal接枝比的增大，DOX/HA-Gal的粒径增大，Zeta电势升高，包封率增加，肿瘤细胞杀伤率提高。</p><p>关键词 :肝癌，海藻酸纳米粒，半乳糖，药物递送，DOX</p><disp-formula id="hanspub.17565-formula3"><graphic xlink:href="http://html.hanspub.org/file/1-1290076x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>肝癌为常见的恶性肿瘤之一，严重威胁人类健康 [<xref ref-type="bibr" rid="hanspub.17565-ref1">1</xref>] 。目前临床用于治疗肝癌的药物多为细胞毒性药物，选择性差，毒副作用大；此外，多数抗肿瘤药物为疏水性药物，难以跨越生理屏障到达肿瘤细胞，严重影响治疗效果 [<xref ref-type="bibr" rid="hanspub.17565-ref2">2</xref>] 。纳米递送系统可提高药物的体内稳定性和选择性，增强抗肿瘤功效，降低毒副作用 [<xref ref-type="bibr" rid="hanspub.17565-ref3">3</xref>] 。海藻酸生物相容、生物可降解、无免疫原性，富含活性羧基和羟基，易于功能化修饰，已广泛应用于药物递送 [<xref ref-type="bibr" rid="hanspub.17565-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.17565-ref5">5</xref>] 。海藻酸骨架引入长链烷基、芳基等疏水性基团制得两亲性聚合物，溶液中可自组装形成纳米粒包载难溶性药物，作为纳米药物递送系统 [<xref ref-type="bibr" rid="hanspub.17565-ref6">6</xref>] 。根据不同类型的肿瘤组织特点，通过受体介导、抗原-抗体特异性相互作用可实现对肿瘤细胞的主动靶向 [<xref ref-type="bibr" rid="hanspub.17565-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.17565-ref8">8</xref>] 。肝癌细胞表面的去唾液酸糖蛋白受体可特异性识别半乳糖基团 [<xref ref-type="bibr" rid="hanspub.17565-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.17565-ref10">10</xref>] ，故半乳糖修饰的纳米粒可主动靶向肝细胞。</p><p>本试验以海藻酸为亲水骨架、十六醇为疏水组分、半乳糖(Gal)为肝癌靶向分子制备两亲性聚合物，水中可自组装形成纳米粒(图1)。以DOX为模型药物，研究不同Gal接枝比HA-Gal纳米粒理化性质，释药规律和肿瘤细胞生长抑制功效。</p></sec><sec id="s4"><title>2. 仪器和试剂</title><p>Advance DMX 500型核磁共振波谱仪(400 MHz，德国Bruker公司)；VEGA TS 5136MM型可变真空扫描电子显微镜(捷克TESCAN公司)；TGA 1型热重分析仪(瑞士Mettler Toledo公司)；Zetasizer Nano ZS90型激光粒度仪(英国Malvern公司)；Varioskan Flash 3001型酶标仪(美国Thermofisher公司)；Nexus 470型傅立叶变换红外光谱仪(美国Nicolet公司)；Scientz-II D型超声波细胞粉碎机(宁波新芝生物科技股份有限公司)；HP6890(PLUS)型气象色谱仪(美国HP公司)。</p><p>十二烷基苯磺酸钠(SDS)、海藻酸钠(sodium alginate, NaAlg)、十六醇、4-二甲基氨基吡啶(4-(N,N- dimethylamino)pyridine, DMAP)、二甲基甲酰胺(dimethylformamide, DMF)、4-甲苯磺酸(p-toluenesulfonic acid, TSA) (国药化学试剂有限公司)；阿霉素(doxorubicin hydrochloride, DOX&#183;HCl) (浙江海正药业股份有限公司)；1-乙基-3-(3-二甲氨丙基)碳二亚胺盐酸盐(N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, EDC&#183;HCl)、N-羟基琥珀酰亚胺(N-Hydroxysuccinimide, NHS) (上海源聚生物科技有限公司)；</p><p>图1. DOX/HA-Gal纳米粒的制备过程示意图</p><p>半乳糖胺盐酸盐(D-(+)-Galactosaminehydrochloride, Gal)、噻唑蓝(3-(4,5-Dimethyl-2-Thiazolyl)-2,5-Diphenyl Tetrazolium Bromide, MTT) (美国Sigma公司)；透析袋(MWCO 3.5 kDa，上海绿鸟科技发展有限公司)。</p><p>QGY-7703细胞(人肝癌细胞，中国科学院上海生命科学研究院)。</p></sec><sec id="s5"><title>3. 方法与结果</title><sec id="s5_1"><title>3.1. 两亲性海藻酸酯(HA)的制备</title><p>HA的制备方法参照文献 [<xref ref-type="bibr" rid="hanspub.17565-ref6">6</xref>] ：称取0.5 g NaAlg和0.5 g TSA，加至35 ml DMF，55℃搅拌30 min，依次加入0.3 g EDC、3.0 g十六醇，55℃反应30 h；加入4倍体积乙醇，室温搅拌30 min，8000 r/min离心20 min得到沉淀，将沉淀用无水乙醇洗涤三次，离心，溶解，透析3 d，冻干得产物HA。图2为NaAlg和HA的热重分析(Thermogravimetric Analysis, TGA)曲线图。</p><p>由图可知：NaAlg和HA均表现为两阶段失重过程，第一阶段为50℃~180℃，这主要为分子中吸附和结合水脱除所致。NaAlg第二阶段失重从216℃开始，并持续到270℃，为羧基热分解脱去CO<sub>2</sub>及相邻羟基脱水造成；相比NaAlg，HA失重更明显，是由于酯键受热分解释放CO<sub>2</sub>、相邻羟基脱去水分子，同时侧链受热分解成小分子，说明十六醇成功接枝至NaAlg。</p></sec><sec id="s5_2"><title>3.2. 半乳糖(Gal)修饰的HA (HA-Gal)制备</title><p>将40 mg HA溶于10 ml去离子水，分别加入4、8和16 mg半乳糖胺，加适量的EDC和NHS (n(EDC): n(NHS):n(半乳糖胺) = 1.2:1.2:1)，于室温反应24 h，透析、冷冻干燥，分别命名为HA-Gal1、HA-Gal2和</p><p>图2. 标准试验系统结果曲线</p><p>HA-Gal3。图3为NaAlg、HA、HA-Gal1、HA-Gal2和HA-Gal3傅里叶变换红外(Fourier Transform Infrared Spectrometer, FT-IR)图谱。</p><p>与NaAlg谱线相比，HA谱线中出现了一些新的吸收峰，1686 cm<sup>−1</sup>和1296 cm<sup>−1</sup>处的小尖峰为酯基中的C=O和C-O伸缩振动峰，说明HA合成。与HA相比，由于HA-Gal中N-H的伸缩振动，HA-Gal 3430 cm<sup>−1</sup>处的宽峰发生红移；1610 cm<sup>−1</sup>处的强峰为C=O和酰胺I相互叠加的结果。</p><p>图4为HA、HA-Gal1、HA-Gal2和HA-Gal3的<sup>1</sup>H-NMR图谱。3.6~5.1 ppm处的信号峰为NaAlg的氢峰。HA图谱中1.6~2.0 ppm处为HA侧链上亚甲基氢峰，1.0~1.3 ppm处为HA侧链上甲基氢峰，亦说明HA合成。HA-Gal图谱3.0~4.0 ppm处为半乳糖胺的特征峰。配制一系列标准浓度的Gal甲苯溶液，通过气相色谱测定不同浓度溶液的峰面积，然后进行线性拟合，得到Gal的标准曲线(检测器：FID，毛细管色谱柱：HP-INNOWAX，30 m &#215; 0.25 mm &#215; 0.25mm。汽化室温度：250℃，检测器温度：280℃，用高纯氮(99.99%)作为载气。色谱柱初温120℃，保持1 min，然后，以10℃/min的升温速率升至230℃，保持3 min。分流比：10:1，进样量：1 ml)。分别称取10 mg HA-Gal样品溶解在1 mol/L的NaOH溶液中，60℃下搅拌24 h然后加入适量甲苯，再充分搅拌1 h，3000 rpm分离，移取上层有机相，重复三次，将上层液进行气相色谱分析。根据气相色谱得到的峰面积计算出甲苯中Gal的浓度，最后计算得到HA-Gal1、HA-Gal2和HA-Gal3的Gal接枝比分别为3.4%、7.8%和11.4% [<xref ref-type="bibr" rid="hanspub.17565-ref11">11</xref>] 。</p></sec><sec id="s5_3"><title>3.3. 纳米粒的制备和表征</title><p>HA-Gal水中可自组装形成以十六醇为疏水核心、海藻酸和半乳糖为亲水外壳的核-壳结构纳米粒，疏水核心有利于包载难溶性药物。分别取2 ml (2 mg/ml) HA、HA-Gal1、HA-Gal2和HA-Gal3溶液，超声(120 W) 15 min，得纳米粒悬液，加入80 ml (10 mg/ml) DOX溶液，超声(120 W) 15 min，即得载DOX纳米粒悬液，分别记为DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3。分别离心，收集上清，测定吸光值，计算DOX包封率(encapsulation efficiency, EE)和载药量(loading capacity，LC，质量分数)。各载药纳米粒粒径、Zeta电势、EE和LC见表1。</p><p>图3. NaAlg、HA、HA-Gal1、HA-Gal2和HA-Gal3的FT-IR图谱</p><p>图4. HA、HA-Gal1、HA-Gal2和HA-Gal3的<sup>1</sup>H NMR图谱</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Particle size, Zeta potentials, EE and LC of DOX/HA, DOX/HA-Gal1, DOX/HA-Gal2 and DOX/HA-Gal3 (, n = 3</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >样品</th><th align="center" valign="middle"  colspan="2"  >粒径 (nm)</th><th align="center" valign="middle"  rowspan="2"  >Zeta电势(mV)</th><th align="center" valign="middle" >EE (%)</th><th align="center" valign="middle" >LC (%)</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >空白纳米粒</td><td align="center" valign="middle" >包载DOX</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >DOX/HA</td><td align="center" valign="middle" >172.4 &#177; 1.7</td><td align="center" valign="middle" >183.4 &#177; 1.8</td><td align="center" valign="middle" >−53.7 &#177; 0.5</td><td align="center" valign="middle" >79.4 &#177; 0.7</td><td align="center" valign="middle" >13.7 &#177; 0.1</td></tr><tr><td align="center" valign="middle" >DOX/HA-Gal1</td><td align="center" valign="middle" >170.8 &#177; 1.2</td><td align="center" valign="middle" >211.2 &#177; 4.9</td><td align="center" valign="middle" >−50.0 &#177; 0.4</td><td align="center" valign="middle" >77.5 &#177; 1.4</td><td align="center" valign="middle" >13.4 &#177; 0.2</td></tr><tr><td align="center" valign="middle" >DOX/HA-Gal2</td><td align="center" valign="middle" >182.7 &#177; 7.4</td><td align="center" valign="middle" >231.4 &#177; 6.0</td><td align="center" valign="middle" >−37.1 &#177; 0.8</td><td align="center" valign="middle" >78.2 &#177; 0.6</td><td align="center" valign="middle" >13.5 &#177; 0.1</td></tr><tr><td align="center" valign="middle" >DOX/HA-Gal3</td><td align="center" valign="middle" >236.1 &#177; 6.3</td><td align="center" valign="middle" >245.3 &#177; 5.1</td><td align="center" valign="middle" >−29.8 &#177; 0.8</td><td align="center" valign="middle" >80.1 &#177; 0.3</td><td align="center" valign="middle" >13.8 &#177; 0.1</td></tr></tbody></table></table-wrap><p>表1. DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3的平均粒径、Zeta电势、EE和LC (<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/1-1290076x15_hanspub.png" xlink:type="simple"/></inline-formula>, n = 3)</p><p>由表可知，随着Gal接枝比的增大，纳米粒粒径增大，这可能由于Gal修饰使表面亲水层增厚 [<xref ref-type="bibr" rid="hanspub.17565-ref12">12</xref>] ；同时Zeta电势增加，可能由于海藻酸骨架游离的羧基随Gal接枝比增大而减少。以扫描电镜(scanning electron microscope, SEM)观察其形貌，可见DOX/HA-Gal2成球形，大小约为200 nm (图5)。</p></sec><sec id="s5_4"><title>3.4. 体外释放</title><p>分别量取1 ml 1 mg/ml DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3纳米粒悬液(按“3.3”项下方法制备)，加至透析袋中(MWCO 3500 Da)，浸入50 ml 0.2 mol/mL PBS (pH 7.4)，37℃、100 r/min振荡温育。分别于0.5、1、2、4、6、8、10、12、24和48 h取样1 ml，测定荧光强度。每次取样后补加1 ml新鲜PBS。由标准曲线得DOX含量，并计算累计释放量(%)。如图6所示，DOX物理包埋于纳米粒后的释药行为呈二相性，即包括初期突释和后期的缓释；前期的突释可能为少量游离及纳米粒表面粘附的DOX快速释放所致，DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3的DOX 48 h累计释放分别达到80%、82%、88%和93%。</p></sec><sec id="s5_5"><title>3.5. 细胞摄取</title><p>按2.3项下方法制备含DOX的纳米粒。以1 &#215; 10<sup>5</sup>细胞/孔的密度接种QGY-7703细胞至24孔板，37℃、5% CO<sub>2</sub>培养24 h；每3孔为一组，按每孔5 mg DOX加入纳米粒，37℃、5% CO<sub>2</sub>分别培养0.5、2和4 h；吸弃孔内液体，以0.2 mol/L PBS (pH 7.4)洗涤三次，加入0.5 ml 0.5% (w/v) SDS溶液(pH 8.0)，37℃、100 r/min振荡培养30 min以裂解细胞；酶标仪测定细胞裂解液中DOX含量，Lowry法测定蛋白质含量。摄取量以每1 mg蛋白质含DOX的量(mg)表示(mg/mg)。</p><p>纳米粒粘附至细胞表面后会被细胞内化，摄取入胞，细胞摄取效率和药物递送效率正相关 [<xref ref-type="bibr" rid="hanspub.17565-ref13">13</xref>] 。</p><p>图7为QGY-7703细胞对纳米粒的摄取试验结果，可见在QGY-7703细胞中，纳米粒在0.5~4 h内可提高药物的细胞摄取量，且摄取量随Gal接枝比的增加而增加，其可能为靶向配体Gal修饰度和纳米粒的粒径、电势等物理性质共同作用的结果。</p></sec><sec id="s5_6"><title>3.6. 细胞毒性试验</title><p>以1 &#215; 10<sup>4</sup>细胞/孔的密度接种QGY-7703细胞至96孔板，37℃、5% CO<sub>2</sub>培养24 h；更换新鲜培养基，每3孔为一组，加入终浓度分别为25、50、250和500 mg/ml的空白纳米粒，以加等体积0.2 mol/L PBS (pH 7.4)为对照，37℃、5% CO<sub>2</sub>培养48 h；MTT法测定细胞存活率。</p><p>图8为QGY-7703细胞与不同浓度空白纳米粒共培养48 h的存活率，可见在25~500 mg/ml浓度范围内纳米粒对细胞活力无显著影响(p &gt; 0.05)，可确保后续体外细胞试验结果的准确性。</p><p>图5. DOX/HA-Gal2的SEM照片</p><p>图6. DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3体外释放曲线(n = 3)</p><p>图7. QGY-7703细胞对纳米粒的摄取(n = 3)</p><p>图8. QGY-7703细胞分别与空白纳米粒共培养48 h后的细胞存活率(n = 3)</p></sec><sec id="s5_7"><title>3.7. 体外细胞抑制</title><p>按2.6项下培养细胞，每6孔为一组，分别加入适量游离DOX、DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3纳米粒悬液，使孔内DOX终浓度分别为0.1、0.2、0.5、1、2和5 mg/ml，以加入0.2 mol/L PBS (pH 7.4)的细胞为阴性对照，37℃、5% CO<sub>2</sub>培养48 h；用MTT法测定各试验组相对细胞存活率，计算半数抑制浓度(IC<sub>50</sub>)。</p><p>图9为QGY-7703细胞分别与游离DOX溶液和纳米粒共培养48 h后的细胞存活率，可见细胞存活率随药物浓度升高而降低。DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3组的细胞存活率显著低于游离DOX组，表明纳米粒可增强药物的肿瘤细胞抑制作用。游离DOX、DOX/HA、DOX/HA-Gal1、DOX/HA-Gal2和DOX/HA-Gal3的IC<sub>50</sub>分别为1.12、0.68、0.64、0.51和0.46 mg/ml，表明体外抗增殖能力随着靶向配体接枝比的增加而增强，与细胞摄取结果一致，纳米粒提高了DOX的肿瘤细胞摄取效率，更多药物入胞，抑制肿瘤细胞增殖。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>用十六醇对海藻酸进行修饰，制备得到两亲性HA，半乳糖胺的氨基与HA的羧基缩合形成酰胺键，制得HA-Gal，HA-Gal水中自组装形成纳米粒，超声条件下包载抗肿瘤药物DOX，得到具有纳米尺度的DOX/HA-Gal。该纳米粒水化后粒径约为200 nm，具有良好的单分散性，随Gal接枝比的增加，纳米粒表面靶向配体与受体的结合能力增强，通过特异性受体介导的内吞作用主动转运入胞，实现纳米粒的主动靶向，同时Zeta电势绝对值降低，与荷负电的细胞表面静电排斥减弱，更有利于细胞的摄取，更多药物进入胞内，抑制肿瘤细胞增殖。此外，Gal修饰度高的纳米粒药物释放更快，高效入胞后，胞内药物浓度提高，更有利于实现高效的细胞抑制。总之DOX/HA-Gal3具有更强的肿瘤细胞增殖抑制功效，其可归因于表面靶向配体修饰度、纳米粒自身粒径、电势和药物释放等理化性质共同作用的结果，HA-Gal3纳米粒有望作为理想的靶向抗肿瘤药物递送载体用于肿瘤治疗。</p><p>图9. QGY-7703细胞分别载药纳米粒共培养48 h后的细胞存活率(n = 6)</p></sec><sec id="s7"><title>文章引用</title><p>李政雄,吴晓盈. 半乳糖修饰的海藻酸纳米载体构建及其抗肿瘤功效 Fabrication of Galactosylated Alginate Nanoparticles as Drug Delivery System for Hepatocellular Carcinoma[J]. 纳米技术, 2016, 06(02): 23-32. http://dx.doi.org/10.12677/NAT.2016.62004</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.17565-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917.  
&lt;br&gt;http://dx.doi.org/10.1002/ijc.25516</mixed-citation></ref><ref id="hanspub.17565-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ma, S., Jiao, B., Liu, X., Yi, H., Kong, D., Gao, L., Zhao, G., Yang, Y. and Liu, X. (2010) Approach to Radiation Therapy in Hepatocellular Carcinoma. Cancer Treatment Reviews, 36, 157-163.  
&lt;br&gt;http://dx.doi.org/10.1016/j.ctrv.2009.11.008</mixed-citation></ref><ref id="hanspub.17565-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ma, P. and Mumper, R.J. (2013) Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review. Nano Today, 8, 313-331. &lt;br&gt;http://dx.doi.org/10.1016/j.nantod.2013.04.006</mixed-citation></ref><ref id="hanspub.17565-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J.-S., Xie, Y.-J. and He, W. (2011) Research Progress on Chemical Modification of Alginate: A Review. Carbohydrate Polymers, 84, 33-39. &lt;br&gt;http://dx.doi.org/10.1016/j.carbpol.2010.11.048</mixed-citation></ref><ref id="hanspub.17565-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Li, Q., Liu, C.-G. and Yu, Y. (2015) Separation of Monodisperse Alginate Nanoparticles and Effect of Particle Size on Transport of Vitamin E. Carbohydrate Polymers, 124, 274-279. &lt;br&gt;http://dx.doi.org/10.1016/j.carbpol.2015.02.007</mixed-citation></ref><ref id="hanspub.17565-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J.S., Zhou, Q.Q. and He, W. (2013) Amphipathicity and Self-Assembly Behavior of Amphiphilic Alginate Esters. Carbohydrate Polymers, 92, 223-227. &lt;br&gt;http://dx.doi.org/10.1016/j.carbpol.2012.08.100</mixed-citation></ref><ref id="hanspub.17565-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, M. and Thanou, M. (2010) Targeting Nanoparticles to Cancer. Pharmacological Research, 62, 90-99.  
&lt;br&gt;http://dx.doi.org/10.1016/j.phrs.2010.03.005</mixed-citation></ref><ref id="hanspub.17565-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Byrne, J.D., Betancourt, T. and Brannon-Peppas, L. (2008) Active Targeting Schemes for Nanoparticle Systems in Cancer Therapeutics. Advanced Drug Delivery Reviews, 60, 1615-1626. &lt;br&gt;http://dx.doi.org/10.1016/j.addr.2008.08.005</mixed-citation></ref><ref id="hanspub.17565-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">D’Souza, A.A. and Devarajan, P.V. (2015) Asialoglycoprotein Receptor Mediated Hepatocyte Targeting—Strategies and Applications. Journal of Controlled Release, 203, 126-139. &lt;br&gt;http://dx.doi.org/10.1016/j.jconrel.2015.02.022</mixed-citation></ref><ref id="hanspub.17565-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X.Q., Wang, X.L., Zhang, P.C., Liu, Z.L., Zhuo, R.X., Mao, H.Q. and Leong, K.W. (2005) Galactosylated Ternary DNA/Polyphosphoramidate Nanoparticles Mediate High Gene Transfection Efficiency in Hepatocytes. Journal of Controlled Release, 102, 749-763. &lt;br&gt;http://dx.doi.org/10.1016/j.jconrel.2004.10.024</mixed-citation></ref><ref id="hanspub.17565-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J.S. and He, W. (2012) Synthesis of Lauryl Grafted Sodium Alginate and Optimization of the Reaction Conditions. International Journal of Biological Macromolecules, 50, 428-431.  
&lt;br&gt;http://dx.doi.org/10.1016/j.ijbiomac.2011.12.027</mixed-citation></ref><ref id="hanspub.17565-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lin, A., Liu, Y., Huang, Y., Sun, J., Wu, Z., Zhang, M. and Ping, Q. (2008) Glycyrrhizin Surface-Modified Chitosan Nanoparticles for Hepatocyte-Targeted Delivery. International Journal of Pharmaceutics, 359, 247-253.  
&lt;br&gt;http://dx.doi.org/10.1016/j.ijpharm.2008.03.039</mixed-citation></ref><ref id="hanspub.17565-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Huang, M., Fong, C.W., Khor, E. and Lim, L.Y. (2005) Transfection Efficiency of Chitosan Vectors: Effect of Polymer Molecular Weight and Degree of Deacetylation. Journal of Controlled Release, 106, 391-406.  
&lt;br&gt;http://dx.doi.org/10.1016/j.jconrel.2005.05.004</mixed-citation></ref></ref-list></back></article>